Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China · Delayed Price · Currency is CNY 5.40
-0.22 (-3.91%)
At close: Sep 9, 2026
SHA:688373 Revenue
Shanghai MicuRx Pharmaceutical had revenue of 47.47M CNY in the quarter ending June 30, 2026, with 40.64% growth. This brings the company's revenue in the last twelve months to 164.33M, up 20.39% year-over-year. In the year 2025, Shanghai MicuRx Pharmaceutical had annual revenue of 141.77M with 8.83% growth.
Revenue (ttm)
164.33M
Revenue Growth
+20.39%
P/S Ratio
21.56
Revenue / Employee
989.96K
Employees
166
Market Cap
3.54B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 141.77M | 11.50M | 8.83% |
| Dec 31, 2024 | 130.27M | 39.50M | 43.51% |
| Dec 31, 2023 | 90.78M | 42.57M | 88.31% |
| Dec 31, 2022 | 48.21M | 40.55M | 529.33% |
| Dec 31, 2021 | 7.66M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Well Pharmaceutical Group | 1.40B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Huaren Pharmaceutical | 1.30B |
| PKU HealthCare Corp.,Ltd. | 972.17M |
| Nanjing Hicin Pharmaceutical | 726.62M |
| Tibet AIM Pharm. | 684.45M |
| Wuhan Hiteck Biological Pharma Co.,Ltd | 491.90M |
| Lionco Pharmaceutical Group | 408.33M |